GLP1R and obesity due to melanocortin 4 receptor deficiency: However, a recent retrospective cohort study, which included 240,618 overweight or obese patients who were prescribed either semaglutide, or non-GLP1R-agonist anti-obesity medications, did not find increased risk of suicidal ideation with semaglutide use (136).